内科胸腔镜下治疗联合胸腔内注入尿激酶对结核性包裹性胸膜炎患者胸膜厚度的影响及疗效分析  

Analysis of Pleural Thickness and Effectiveness of Internal Thoracoscopic Treatment Combined with Intrapleural Injection of Urokinase in Patients with Tuberculous Encapsulated Pleuritis

作　　者：朱聪 ZHU Cong(Tuberculosis Internal Medicine Department,Shandong Provincial Public Health Clinical Center,Shandong Jinan 250013)

机构地区：[1]山东省公共卫生临床中心结核内科,山东济南250013

出　　处：《中国医疗器械信息》2024年第7期102-104,共3页China Medical Device Information

摘　　要：目的:分析结核性包裹性胸膜炎患者开展内科胸腔镜下治疗联合胸腔内注入尿激酶的临床疗效以及胸膜厚度影响。方法:选定2018年1月~2022年12月收治的结核性包裹性胸膜炎患者60例为研究对象,应用随机法每组划定30例,设为对照组(常规治疗)和观察组(内科胸腔镜下治疗联合胸腔内注入尿激酶),比较临床治疗效果检测值;治疗前后肺功能测评值;不良反应监测情况;治疗前后胸膜厚度变化。结果:①观察组所获临床疗效数据值更高,高于对照组,存在统计学意义(P<0.05);②治疗前,两组肺功能测评值无差异(P>0.05);治疗后,所有人员肺功能均有好转趋势,且观察组各项数据值优于对照组,存在统计学意义(P<0.05);③观察组出现的不良反应情况更低,数据值低于对照组,存在统计学意义(P<0.05);④治疗后,观察组胸膜厚度低于对照组,存在统计学意义(P<0.05)。结论:结核性包裹性胸膜炎应用内科胸腔镜下治疗联合胸腔内注入尿激酶,临床治疗效果理想,肺功能有好转,胸膜厚度削减,安全性更高,不良反应低。Objective:To analyze the effectiveness of internal thoracoscopic treatment combined with intrapleural injection of urokinase in patients with tuberculous encapsulated pleurisy and the impact of pleural thickness.Methods:60 patients with tuberculous enveloping pleurisy admitted from January 2018 to December 2022 were selected as the study subjects.Thirty patients were randomly divided into a control group(conventional treatment)and an observation group(internal thoracoscopic treatment combined with intrapleural injection of urokinase).Compare clinical treatment efficacy detection values;Pulmonary function assessment values before and after treatment;Adverse reaction monitoring status;Changes in pleural thickness before and after treatment.Results:①The clinical efficacy data obtained by the observation group were higher than those of the control group,with statistical significance(P<0.05);②Before treatment,there was no difference in lung function evaluation values between the two groups(P>0.05);After treatment,all personnel showed a trend of improvement in lung function,and the observation group had better data values than the control group,with statistical significance(P<0.05);③The observation group had lower incidence of adverse reactions and lower data values than the control group,with statistical significance(P<0.05);④After treatment,the pleural thickness in the observation group was lower than that in the control group,with statistical significance(P<0.05).Conclusion:The application of internal thoracoscopy combined with intrapleural injection of urokinase for the treatment of tuberculous encapsulated pleurisy has ideal clinical results,improved lung function,reduced posterior pleural thickness,higher safety,and lower adverse reactions.

关 键 词：内科 胸腔镜 胸腔 尿激酶 结核性包裹性胸膜炎 胸膜厚度 

分 类 号：TH773[机械工程—仪器科学与技术]